Home Meeting Coverage ASH Annual Meeting ASH Annual MeetingMeeting CoverageMultimedia Stephen M. Ansell, MD, PhD: Nivolumab Moves to Hematology Tuesday, March 7, 2017 Dr. Ansell, a speaker in the Special Education Session on Newly Approved Drugs, discusses the growing role of nivolumab in hematologic malignancies. Advertisement Recent Articles issuepost Wednesday, April 24, 2019 Is there a genetic risk for familial CLL? Tuesday, April 23, 2019 This month, Kanti R. Rai, MD, discusses familial chronic lymphocytic leukemia. And don't forget to check out next month's clinical dilemma - send in your... Venetoclax Plus Obinutuzumab Confers High MRD-Negative Rates in CLL Tuesday, April 23, 2019 Results from a phase Ib study demonstrated that the combination of the BCL2 inhibitor venetoclax with the anti-CD20 monoclonal antibody obinutuzumab was safe and... Remembering Arthur Rosenberg, Dorothy Tuan Lo, and more Tuesday, April 23, 2019 Remembering Arthur Rosenberg (1935 – 2018) Arthur Rosenberg, MD, FRCPC, a former chief of hematology at the Jewish General Hospital (JGH) in Montreal, Quebec, passed... Pulling Back the Curtain: Clara Bloomfield, MD Tuesday, April 23, 2019 In this edition, Clara Bloomfield, MD, talks about being on the right project at the right time and having academia in her blood.Where did... Current Issue April 2019, Volume 5, Issue 5 Monday, April 1, 2019 This issue features a look at the pitfalls of presenting and interpreting clinical trial data, the latest advances in transplant presented at the 2019 TCT Meetings, and more.